Replies to post #531282 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

A new publication would be the most logical reason but it always seems like we read the tea leaves and then find out they were wrong.

Right before May 10, 2022 the idea of releasing TLD without a company PR was almost unheard of and given we had been fed the notion the journal article was needed to legitimize TLD and inoculate us from a short attack we thought a JA was coming too.

It took months of relentless arguing to normalize what happened but it is still really not normal.

I suspect that if we have a bare presentation by Dr. Liau and no JA or TLD PR by NWBO there will be the same efforts to make that what we should have expected. The browbeating is so good it makes you doubt your lived experience from time to time.

[Dr Bala]

The new authors seem to be extremely qualified.

George Anstass, MD – Associate Professor, Washington University
Joo Yeon Nam – Rush Medical College
Stephanie Wagner – Columbus Regional Health
Ian Y. Lee, MD – Neurosurgeon, Henry Ford Health
Darren Lovick – Advent Health
Nina Martinez, MD – Assistant Professor of Neurology, Jefferson University
Pierre Giglio, M.D. – Associate Professor, Ohio State University Comprehensive Cancer Center
Oleg Gligich – Mount Sinai Medical Center
Minou Nadji-Ohl – Klinikum der Landeshauptstadt Stuttgart
Lhagva Sanchin – Bergmannstrost